We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




AI Tool Detects Early Signs of Blood Mutations Linked to Cancer and Heart Disease

By LabMedica International staff writers
Posted on 27 Aug 2025

Deep inside the body, clusters of mutated blood cells can slowly form without symptoms, affecting about one in five older adults. More...

This condition, known as clonal hematopoiesis of indeterminate potential (CHIP), increases the likelihood of leukemia more than tenfold and raises the risk of heart disease up to fourfold. Because it often goes undetected for years, finding CHIP earlier could allow for proactive monitoring or preventive care to reduce risk. Now, an artificial intelligence (AI) tool can find early signs of blood mutations linked to cancer and heart disease.

The AI tool called UNISOM—short for UNIfied SOmatic calling and Machine learning—has been developed by researchers at Mayo Clinic (Rochester, MN, USA) to identify CHIP-related mutations in standard genetic datasets. Unlike earlier methods that required advanced sequencing, this innovation allows clinicians and scientists to uncover subtle DNA changes using existing data, broadening research and potential clinical use.

UNISOM was evaluated in a study published in Genomics, Proteomics & Bioinformatics. The tool successfully detected nearly 80% of CHIP mutations using whole-exome sequencing, which focuses on protein-coding DNA. It also identified mutations present in fewer than 5% of blood cells when tested on whole-genome sequencing data from the Mayo Clinic Biobank, outperforming conventional techniques that often miss such small but significant changes.

By detecting CHIP at its earliest molecular stages, the approach offers a powerful new way to study disease progression and guide patient care. The researchers emphasized that integrating this tool into larger and more diverse datasets could strengthen predictions, enabling earlier detection of high-risk individuals and more precise treatment decisions in the clinic.

"We're engineering a path from genomic discovery to clinical decision-making," said Shulan Tian, Ph.D., the co-senior author and a bioinformatician at Mayo Clinic. "It's rewarding to help bring these discoveries closer to clinical care, where they can inform decisions and support more precise treatment."


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
New
Chromogenic Culture System
InTray™ COLOREX™ ECC
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: The GenoPredict assay from Predicta Biosciences is available to Tempus Life Sciences partners to support exploratory research and clinical development programs (photo courtesy of Shutterstock)

Partnership Expands Ultrasensitive WGS Assay for for Hematologic Malignancies and MRD Monitoring

Tempus AI and Predicta Biosciences announced the commercial expansion of a co-branded whole‑genome sequencing assay GenoPredicta, which is intended for comprehensive genomic characterization of hematologic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.